middle.news
INOVIQ puts Sonic Healthcare behind its US ovarian cancer test
8:32am on Monday 2nd of November, 2026 AEDT
•
Healthcare
Read Story
INOVIQ puts Sonic Healthcare behind its US ovarian cancer test
8:32am on Monday 2nd of November, 2026 AEDT
Key Points
Sonic Healthcare USA to optimise and validate EXO-OC at its Rye Brook, New York laboratory
Non-exclusive option for a future US Laboratory Developed Test licence
No commercial licence or broader partnership commitment has been made
Updated algorithm reported 92.3% stage I/II sensitivity at 98% specificity
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Inoviq (ASX:IIQ)
OPEN ARTICLE